Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Chen, Robert; Luigi Zinzani, Pier; A. Fanale, Michelle; Armand, Philippe; A. Johnson, Nathalie; Brice, Pauline; Radford, John; Ribrag, Vincent; Molin, Daniel; P. Vassilakopoulos, Theodoros; Tomita, Akihiro; von Tresckow, Bastian; A. Shipp, Margaret; Zhang, Yinghua; D. Ricart, Alejandro; Balakumaran, Arun; H. Moskowitz, Craig; the KEYNOTE-087, for

doi:10.1200/jco.2016.72.1316

Public

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Published in Journal of Clinical Oncology • Apr 25, 2017

Authors:

Robert Chen

Pier Luigi Zinzani

Michelle A. Fanale

Abstract

Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory class...

Subject

Pembrolizumab

Medicine

Cohort

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!